Uploaded November 2023 | Updated September 2026, 4 days ago
Speaker: Drew Endy
What is a better question than where did SARS-CoV-2 come from?
Why can we routinely forbid research with live smallpox but not influenza or coronavirus?
Why do well-intentioned elected officials believe centralized DNA synthesis screening will improve biosecurity?
How can we create or strengthen trust in biotechnology-based operations, transactions, and offerings?
We live today within a collapsing biosecurity bubble, inflated by standing down the US offensive bioweapons program under Nixon but deflating since.
Can we responsibly steward development and deployment of 21st century biotechnologies, sufficient to enable planetary-scale flourishing, without veering into Hobbesian despair?
What lessons can be learned from what the physics and policy communities did or did not accomplish in the 1930s?
Or the internet leaders did or failed to do in the 1980s?
Or the AI community failed to do in the 2010s?
Are there practical paths forward besides reacting to unilateral innovators and actors?
Speaker: Drew Endy
What is a better question than where did SARS-CoV-2 come from?
Why can we routinely forbid research with live smallpox but not influenza or coronavirus?
Why do well-intentioned elected officials believe centralized DNA synthesis screening will improve biosecurity?
How can we create or strengthen trust in biotechnology-based operations, transactions, and offerings?
We live today within a collapsing biosecurity bubble, inflated by standing down the US offensive bioweapons program under Nixon but deflating since.
Can we responsibly steward development and deployment of 21st century biotechnologies, sufficient to enable planetary-scale flourishing, without veering into Hobbesian despair?
What lessons can be learned from what the physics and policy communities did or did not accomplish in the 1930s?
Or the internet leaders did or failed to do in the 1980s?
Or the AI community failed to do in the 2010s?
Are there practical paths forward besides reacting to unilateral innovators and actors?
